Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Clinical evidence

Transform-HTN

50 evidence topics · 14 sources

Objective
Location and study date
Study design
Design details in the ClinicalTrials.gov record
FieldQuoted record
Primary purpose“Treatment”
Allocation“Non-Randomized”
Interventional model“Single Group Assignment”
Masking“None (Open Label)”
Phase“Phase 3”
Enrollment“1076”
Eligibility criteria
Treatment
Study outcomes
Rationale for using change in automated office systolic blood pressure as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size

No evidence found.

Number randomized in the randomized treatment withdrawal substudy

No evidence found.

Description of analysis sets
Results
Participant disposition
Participants enrolled from Advance-HTN and Explore-CKD

No evidence found.

Baseline characteristics
Baseline characteristics of the Launch-HTN cohort (safety population)
CharacteristicLorundrostat (N=632)
Age, mean ±SD, years“61.2 ± 10.5”
Female, n (%)“292 (46.2)”
Black or African American, n (%)“155 (24.5)”
Hispanic or Latino, n (%)“248 (39.2)”
BMI ≥30 kg/m2, n (%)“395 (62.5)”
eGFR, mean ±SD, mL/min/1.73 m2“92.7 ± 17.4”
Office SBP, mean ±SD, mmHg“148.5 ± 11.9”
2 antihypertensive drugs, n (%)“262 (41.5)”
3 or more antihypertensive drugs, n (%)“370 (58.5)”
Thiazide or thiazide-like diuretic, n (%)“601 (95.1)”
ACE inhibitor or ARB, n (%)“546 (86.4)”
Calcium channel blocker, n (%)“295 (46.7)”
Beta blockers, n (%)“209 (33.1)”
Efficacy results
Renin-angiotensin-aldosterone system biomarkers at week 48 (not prespecified)
BiomarkerPercent change in geometric mean from baseline at week 48
Serum aldosterone“-54.8%”
Plasma renin activity“+123.9%”
Aldosterone-renin ratio“-79.8%”
Randomized treatment withdrawal substudy: change in automated office systolic blood pressure from week 12 to week 16

No evidence found.

Efficacy in participants enrolled from Advance-HTN and Explore-CKD

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events during the 36-week open-label period
Participants, n (%)Lorundrostat (N=632)
Any treatment-emergent adverse event“413 (65.3)”
Moderate intensity“141 (22.3)”
Severe intensity“20 (3.2)”
Treatment-emergent adverse event leading to study drug withdrawal“37 (5.9)”
Hyperkalemia leading to study drug withdrawal“10 (1.6)”
Any serious adverse event“27 (4.3)”
Death“0”
Treatment-related serious treatment-emergent adverse event (investigator determined)“2 (0.3)”
Hyperkalemia requiring trial drug modification (adverse event of special interest)“32 (5.1)”
Hyponatremia requiring trial drug modification (adverse event of special interest)“28 (4.4)”
Hypotension with symptoms (adverse event of special interest)“13 (2.1)”
Serum potassium >6.0 mmol/L, confirmed per protocol repeat testing“16 (2.5)”
Study limitations
Summary

Transform-HTN is a phase 3, single-group, open-label extension registered with 1,076 participants from three parent studies (Launch-HTN, Advance-HTN, and Explore-CKD). The only results available as of November 2026 are for the Launch-HTN cohort, presented as congress slides and a company press release on November 8, 2026; no peer-reviewed publication and no posted registry results were located, and the record lists a certification or extension request for results submission first submitted on July 15, 2026. Of 808 participants who received lorundrostat in Launch-HTN, 632 (78%) enrolled, so the cohort is limited to participants who completed the parent trial and chose to continue, which may favor participants who tolerated and responded to treatment. The primary endpoint is a within-group change from the Launch-HTN baseline, which includes the 12-week double-blind period; after the 12-week double-blind period there was no concurrent control group except during the 4-week withdrawal substudy, and in Launch-HTN the placebo group's automated office systolic blood pressure fell by 7.9 mm Hg at week 6, so the 17.8 mmHg change at week 48 cannot be attributed entirely to lorundrostat. The efficacy analysis (504 participants) excluded participants randomized to placebo in the withdrawal substudy, whereas the safety analysis included all 632; missing week 48 values were imputed with a shift factor based on the parent trial's placebo group. The randomized treatment withdrawal substudy, the only randomized comparison in the trial, is a registered primary outcome (change in automated office systolic blood pressure from extension week 12 to week 16) and is listed as completed, but neither its sample size nor its results were located in any public document. Only the office systolic blood pressure change and the proportion below 130 mmHg were prespecified; the biomarker results were not. Serum creatinine was measured by an enzymatic assay in Launch-HTN and a Jaffe assay in the extension, which limits comparison of eGFR across the two periods. No quality-of-life or patient-reported outcome was reported, and no results were located for participants who entered from Advance-HTN or Explore-CKD.